Indian Pharma Stocks Drop Amid U.S. Generics Concerns

  Published 10 months ago

Indian pharma stocks fall as Macquarie warns of U.S. generics price erosion and downgrades key firms.

  • NIPHARM drops 1.5% as 17/20 Nifty 50 pharma stocks decline amid rising competition.
  • Macquarie cites easing U.S. drug shortages and increased competition accelerating price erosion.
  • Aurobindo, Cipla, Dr. Reddy's, Lupin downgraded; Q1 results at risk from gRevlimid competition.

You might like these

Dixon Expands in Components with Two Deals

SWREL Q1 Profit Jumps 5x YoY

Hero MotoCorp E-Scooter Battery Rental Faces Criticism

Leadership Shift at Can Fin Homes: CFO Change & New Appointments

India Boosts Energy Storage with Transmission Waivers

Desco Infratech bags ₹6.64 crore orders

Coforge & Fuqua Drive AI Innovation in Enterprises

News that matters the most ⚡